Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART.

European journal of clinical pharmacology - 1 Jul 2009

Bertrand Julie, Treluyer Jean-Marc, Panhard Xavière, Tran Agnes, Auleley Solange, Rey Elisabeth, Salmon-Céron Dominique, Duval Xavier, Mentré France

Abstract excerpt

AIMS: To assess the relationship between genetic polymorphisms and indinavir pharmacokinetic variability and to study the link between concentrations and short-term response or metabolic safety. METHODS: Forty protease inhibitor-naive patients initiating highly active antiretroviral therapy (HAAR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiretroviral Therapy, Highly Active
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Cytochrome P-450 CYP3A

Share to HIV Protease Inhibitors

Share to Indinavir

Share to Metabolic Clearance Rate

Share to Multicenter Studies as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 19440701
DOI: 10.1007/s00228-009-0660-5
PMCID: PMC2908290

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19440701-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART.PMID 19440701Read ↗

Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.Semantic proximity Read ↗

Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.Semantic proximity Read ↗

Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters.Semantic proximity Read ↗

Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.Semantic proximity Read ↗

Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.Semantic proximity Read ↗

Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics.Semantic proximity Read ↗

Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.Semantic proximity Read ↗

A population pharmacokinetic-pharmacogenetic analysis of atazanavir.Semantic proximity Read ↗

Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy.Semantic proximity Read ↗

Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study).Semantic proximity Read ↗

Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children.Semantic proximity Read ↗

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.